The Unisense FertiliTech, a world leader in technology time-lapse for IVF, will be presenting a large-scale analysis of the variables of embryonic development that are associated with the implantation potential at the annual meeting of the European Society of Human Reproduction and Endocrinology (ESHRE) in London from July 7-10. These results will be presented in the exhibition Unisense FertiliTech.
Many clinics that use the system time-lapse EmbryoScope provide information about the development of the embryo and results of clinical treatment for database Unisense FertiliTech. This database is the largest of its kind and contains detailed information about the characteristics of embryonic development in relation to successful implantation and pregnancy.
Based on an agreement with 40 clinics comprising 12,000 embryos transferred, a detailed analysis of 8,000 embryos with known result of implantation was performed. The analysis revealed clear variables that could be used to help select the best embryos for day 2, 3 or 5 transfer. In addition, the intensity of the algorithm risk of chromosomal recently reported by the group CARE Fertility in the paper RBMonline (Campbell et al Reprod.Biomed. Online May 2013, 26 (5) :477-85.) was tested against a large data set and confirmed the results.
Bjørn Molt and Mette Petersen Lægdsmand, experts in data analysis FertiliTech, said: "Although this analysis seems to show convincing trends that are related to the potential development of the embryo, the analysis also reveals the impact of different conditions and cultural practices between clinics. This means that the real criteria for good quality embryo must be individually validated before use.”
The Unisense FertiliTech celebrating 10 years in the development of innovative technologies to improve the selection of embryos in the laboratory fertilization in vitro develops and manufactures the system time-lapse EmbryoScope. The system was approved for clinical use in Europe in 2009 and is the only system time-lapse that is approved by the FDA for clinical use in the USA. The technology is used in clinical routine for more than 275 clinics around the world and has been used for about 60,000 cycles of treatment. It is estimated that more than 10,000 babies have been born using the system EmbryoScope.
In order to allow the clinics to use the full potential of the technology time-lapse, the Unisense FertiliTech continues developing embryo analysis software to improve the results of fertilization in vitro. The scientific director Niels Birger Ramsing says that very early on, we recognized the need for software tools that allow clinics to customize their own valuation models in their clinics and that is why we are at the forefront to provide these tools to help our clients make the best decisions.
The Unisense FertiliTech develops technologies to improve the assessment of human embryos in assisted reproduction. It also develops and manufactures EmbryoScope, a unique time-lapse system, which facilitates improved IVF treatment, flexible work routines and effective communication through comprehensive documentation of embryo development and improvements in growing selection.